# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved i...
Benchmark analyst Aydin Huseynov downgrades Trillium Therapeutics (NASDAQ:TRIL) from Buy to Hold.
Trillium Therapeutics Inc. (“Trillium” or the “Company”) (TSX:TRIL), a clinical stage immuno-oncology company developing innova...
Craig-Hallum analyst Robin Garner downgrades Trillium Therapeutics (NASDAQ:TRIL) from Buy to Hold and lowers the price targe...
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed...
JMP Securities analyst Reni Benjamin downgrades Trillium Therapeutics (NASDAQ:TRIL) from Market Outperform to Market Perform.